Holen Sie sich die Stockscreener-App
1.56
11.86%
-0.21
Handel nachbörslich:
1.52
-0.04
-2.56%
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
Real-World Deployments Signal AI Healthcare Is Ready for Scale - FinancialContent
BioXcel Therapeutics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa
BioXcel Therapeutics stock hits 52-week low at $1.24 - Investing.com Australia
SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement - Revista ADVFN
BioXcel Therapeutics Receives Positive Recommendation from Data - GuruFocus
BTAIBioXcel Therapeutics Provides Clinical and Business Update - mx.advfn.com
BioXcel’s Phase 3 trial of BXCL501 continues as advised by DSMB - Investing.com India
BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq L - GuruFocus
BioXcel Therapeutics granted Nasdaq extension - Investing.com Australia
BioXcel granted an extension for compliance by Nasdaq - Hartford Business Journal
BioXcel Therapeutics granted Nasdaq extension By Investing.com - Investing.com South Africa
BTAI's Phase 3 Trial for BXCL501 Advances Unhindered by Safety Concerns | BTAI Stock News - GuruFocus
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated wit - GuruFocus
Bioxcel Therapeutics Granted Extension To Regain Compliance With Nasdaq Continued Listing Requirement - marketscreener.com
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
BioXcel Therapeutics (BTAI) Granted Extension to Retain Nasdaq Listing - GuruFocus
BioXcel's Breakthrough At-Home Agitation Drug Clears Critical Safety Review, First FDA Approval Possible - Stock Titan
BioXcel Therapeutics (BTAI) Secures Continued Nasdaq Listing | B - GuruFocus
BioXcel Granted Nasdaq Compliance Extension Until September - TipRanks
BioXcel Therapeutics (BTAI) Secures Continued Nasdaq Listing | BTAI Stock News - GuruFocus
BioXcel Gets Critical Nasdaq Reprieve: 4-Month Extension as Phase 3 Trial Results Near - Stock Titan
BioXcel Therapeutics stock hits 52-week low at $0.3 - MSN
Can a $10,000 Investment in SoundHound AI Turn Into $1 Million by 2035? - The Globe and Mail
BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options - The Globe and Mail
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics Advances Clinical Trials Amid Financial Adjustments - TipRanks
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | BTAI Stock News - GuruFocus
BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView
BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BioXcel Therapeutics (BTAI) Reports Major Milestone in BXCL501 T - GuruFocus
BioXcel Therapeutics Q1 2025 Financial Results and Business Update - TradingView
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
IGALMI Marks Significant Market Growth, Reaching New Heights in Treatment Accessibility | DelveInsight - The Malaysian Reserve
Press Release Distribution & PR Platform - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of BioXcel Therapeutics, Inc.(BTAI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.
BioXcel Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
BioXcel Therapeutics stock hits 52-week low at $1.72 By Investing.com - Investing.com Canada
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):